What do systematic reviews say?

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 710 participants
  Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Laser plus sclerotherapy showed no clear difference in adverse events ‐ Hyperpigmentation ( compared with sclerotherapy (low certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 0.83 [0.35, 1.99]
  2 studies · 656 participants
  Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Laser plus sclerotherapy showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (low certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 0.83 [0.21, 3.28]
  2 studies · 656 participants
  Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Laser plus sclerotherapy may leads to higher pain ( compared with sclerotherapy (low certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 2.44 [1.69, 3.55]
  1 study · 596 participants
  Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser therapy vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 593 participants
  Moderate

Laser therapy vs sclerotherapy (any sclerosant)

Laser probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (moderate certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 0.57 [0.4, 0.8]
  4 studies · 262 participants
  Moderate

Laser therapy vs sclerotherapy (any sclerosant)

Laser showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (moderate certainty).

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  RR 1 [0.46, 2.19]
  2 studies · 162 participants
  Moderate

Laser therapy vs sclerotherapy (any sclerosant)

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 100 participants
  Low

Laser therapy vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser therapy vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser therapy vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Endovenous laser ablation (EVLA) vs conventional surgery

Endovenous laser ablation probably leads to lower recanalisation or persistence of reflux at 6 weeks compared with conventional surgery (moderate certainty).

• Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for… 2016 · Cochrane Headline outcomes only
  OR 0.07 [0.02, 0.22]
  3 studies · 289 participants
  Moderate

Endovenous laser ablation (EVLA) vs conventional surgery

Endovenous laser ablation may leads to lower recurrence of reflux at 1 year compared with conventional surgery (low certainty).

• Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for… 2016 · Cochrane Headline outcomes only
  OR 0.24 [0.07, 0.77]
  2 studies · 119 participants
  Low

Endovenous laser ablation (EVLA) vs conventional surgery

Endovenous laser ablation showed no clear difference in clinical evidence of recurrence after 1 year compared with conventional surgery (low certainty).

• Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for… 2016 · Cochrane Headline outcomes only
  OR 0.54 [0.17, 1.75]
  1 study · 99 participants
  Low

Endovenous laser ablation (EVLA) vs conventional surgery

• Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 99 participants
  Moderate

Endovenous laser ablation (EVLA) vs conventional surgery

• Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 265 participants
  Moderate
• Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 99 participants
  Low

Endovenous laser ablation (EVLA) vs conventional surgery

• Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 265 participants
  Moderate